Health Care

CEO Nikolas Stengle sells 20,677 shares of Brookdale Senior Living, raising questions about insider confidence amid the company’s 10.92% monthly decline.

Mark Boulding’s latest PTC Therapeutics buy shows insider confidence and may signal a short‑term uptick, but investors should weigh the firm’s valuation risks.

Coen Steven P. sells 2,403 Ginkgo Bioworks shares at $15, signaling steady insider confidence while the company scales its synthetic‑biology platform and eyes new funding rounds.

Illumina CEO Thaysen Jacob sells 1,303 shares—minor portfolio tweak, not a red flag. Understand why insiders trade and focus on Illumina’s strong growth.

Liquidia insider Bloch sells 235,000 shares amid a patent‑infringement ruling, hinting at portfolio rebalancing rather than a crash.

OMADA insiders’ RSU buys signal board confidence, boosting investor optimism for future growth and product launches.

Waystar CEO Matthew Hawkins executes a Rule 144 buy‑sell plan, buying at $4.14 and selling at $26.23—showing strategic liquidity and confidence in the stock’s upside.

Arbutus Biopharma insider selling signals a strategic shift: CEO, CFO, and top execs sell shares, raising questions about the stock’s future and the impact on investor sentiment.

VAXCYTE insiders, led by Wassil Jim, buy low and sell high—showing confidence in upcoming VAX‑31 data and a new $500M capital raise.

Insider option buys at zero cost signal confidence in Humacyte’s future – investors may spot upside as execs bet on the bio‑tissue platform’s growth.